Matrix metalloproteinases in acute coronary syndromes: Current perspectives

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1192-1205

  Kampoli, Anna Maria ^a   Tousoulis, Dimitris ^a   Papageorgiou, Nikolaos ^a   Antoniades, Charalambos ^a   Androulakis, Emmanuel ^a   Tsiamis, Eleftherios ^a   Latsios, George ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute coronary syndromes; Atherosclerosis; Inflammation; Matrix metalloproteinases; Myocardial infarction; Plaque formation

Indexed keywords

DOXYCYCLINE; EPICATECHIN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; HO 3867; INTERSTITIAL COLLAGENASE; LISINOPRIL; MATRIX METALLOPROTEINASE; MEPRIN; MINOCYCLINE; NEUTROPHIL COLLAGENASE; PD 166793; PIPERIDINE DERIVATIVE; PRAVASTATIN; PYRIMIDINE DERIVATIVE; RO 282653; STROMAL CELL DERIVED FACTOR 1; TETRACYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; CACAO; CELL MIGRATION; DEGRADATION; ENZYME REGULATION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; MACROPHAGE; NONHUMAN; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 84861146114     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011192     Document Type: Article

References (97)

1. Schächinger, V.; Britten, M.B.; Elsner, M.; Walter, D.H.; Scharrer, I.; Zeiher, A.M. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation, 1999, 100(14), 1502-1508.
2. Tousoulis, D.; Davies, G.; Stefanadis, C.; Toutouzas, P.; Ambrose, J.A. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart, 2003, 89(9), 993-997.
3. Tousoulis, D.; Antoniades, C.; Nikolopoulou, A.; Koniari, K.; Vasiliadou, C.; Marinou, K.; Koumallos, N.; Papageorgiou, N.; Stefanadi, E.; Siasos, G.; Stefanadis, C. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest, 2007, 37(8), 623-628.
4. Antoniades, C.; Tousoulis, D.; Vasiliadou, C.; Pitsavos, C.; Chrysochoou, C.; Panagiotakos, D.; Tentolouris, C.; Marinou, K.; Koumallos, N.; Stefanadis, C. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J. Am. Coll. Cardiol., 2005, 46 (6), 1101-1109.
5. Ross, R. In: The pathogenesis of atherosclerosis; Braunwald E, Ed.; W.B. Saunders: Philadelphia, 1992; 4rth edition, pp. 1106-1124.
6. Yamada, N. Plaque Formation and Its Rupture. Internal Medicine, 2000, 39(4), 335-336.
7. Penny, W.J.; Chesebro, J.H.; Heras, M.; Fuster, V. Antithrombotic therapy for patients with cardiac disease. Curr. Probl. Cardiol., 1988, 13(7), 425-513.
8. Fuster, V.; Steele, P.M.; Chesebro, J.H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J. Am. Coll. Cardiol., 1985, 5 (6 Suppl), 175B-184B.
9. Tousoulis, D.; Zisimos, K.; Antoniades, C.; Stefanadi, E.; Siasos, G.; Tsioufis, C.; Papageorgiou, N.; Vavouranakis, E.; Vlachopoulos, C.; Stefanadis, C. Oxidative stress and inflammatory process in patients with atrial fibrillation: the role of left atrium distension. Int. J. Cardiol., 2009, 136(3), 258-262.
10. Mostafa Mtairag, E.; Chollet-Martin, S.; Oudghiri, M.; Laquay, N.; Jacob, M.P.; Michel, J.B.; Feldman, L.J. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc. Res., 2001, 49(4), 882-890.
11. Ardans, J.A.; Blum, A.; Mangan, P.R.; Wientroub, S.; Cannon, R.O. 3rd.; Wahl, L.M. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler. Thromb. Vasc. Biol., 2001, 21(8), 1265-1268.
12. Shah, P.K.; Galis, Z.S. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation, 2001, 104(16), 1878-1880.
13. Moreau, M.; Brocheriou, I.; Petit, L.; Ninio, E.; Chapman, M.J.; Rouis, M. Interleukin-8 mediates down regulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation, 1999, 99(3), 420-426.
14. Pei, D.; Kang, T.; Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem., 2000, 275(43), 33988-33997.
15. Trexler, M.; Briknarová, K.; Gehrmann, M.; Llinás, M.; Patthy, L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem., 2003, 278(14), 12241-12246.
16. Webster, N.L.; Crowe, S.M. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. Journal Of Leukocyte Biology, 2006, 80(5), 1052-1066.
17. Amorino, G.P.; Hoover, R.L. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am. J. Pathol., 1998, 152(1), 199-207.
18. Wesley, R.B. 2nd; Meng, X.; Godin, D.; Galis, Z.S. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler. Thromb. Vasc. Biol., 1998, 18(3), 432-440.
19. Galt, S.W.; Lindemann, S.; Medd, D.; Allen, L.L.; Kraiss, L.W.; Harris, E.S.; Prescott, S.M.; McIntyre, T.M.; Weyrich, A.S.; Zimmerman GA. Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ. Res., 2001, 89(6), 509-516.
20. Hojo, Y.; Ikeda, U.; Takahashi, M.; Sakata, Y.; Takizawa, T.; Okada, K.; Saito, T.; Shimada, K. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J. Mol. Cell. Cardiol., 2000, 32(8), 1459-1468.
21. Dollery, C.M.; McEwan, J.R.; Henney, A.M. Matrix metalloproteinases and cardiovascular disease. Circ. Res., 1995, 77(5), 863-868.
22. George, S.J. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert. Opin. Investig. Drugs., 2000, 9(5), 993-1007.
23. Libby, P.; Sukhova, G.; Lee, R.T.; Galis, Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol., 1995, 25 Suppl 2, S9-S12.
24. Rajavashisth, T.B.; Xu, X.P.; Jovinge, S.; Meisel, S.; Xu, X.O.; Chai, N.N.; Fishbein, M.C.; Kaul, S.; Cercek, B.; Sharifi, B.; Shah, P.K. Membrane type 1 matrix metalloproteinase expression in hu man atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation, 1999, 99(24), 3103-3109.
25. Kong, Y.Z.; Yu, X.; Tang, J.J.; Ouyang, X.; Huang, X.R.; Fingerle- Rowson, G.; Bacher, M.; Scher, L.A.; Bucala, R.; Lan, H.Y. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis, 2005, 178(1), 207-215.
26. Uzui, H.; Harpf, A.; Liu, M.; Doherty, T.M.; Shukla, A.; Chai, N.N.; Tripathi, P.V.; Jovinge, S.; Wilkin, D.J.; Asotra, K.; Shah, P.K.; Rajavashisth, T.B. Increased expression of membrane type 3- matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation, 2002, 106(24), 3024-3030.
27. Lacraz, S.; Nicod, L.P.; Chicheportiche, R.; Welgus, H.G.; Dayer, J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest., 1995, 96(5), 2304-2310.
28. Sasaguri, T.; Arima, N.; Tanimoto, A.; Shimajiri, S.; Hamada, T.; Sasaguri, Y. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis, 1998, 138(2), 247-253.
29. Shapiro, S.D.; Campbell, E.J.; Kobayashi, D.K.; Welgus, H.G. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J. Clin. Invest., 1990, 86(4), 1204-1210.
30. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94(6), 2493-503.
31. Luttun, A.; Lutgens, E.; Manderveld, A.; Maris, K.; Collen, D.; Carmeliet, P.; Moons, L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation, 2004, 109(11), 1408-14.
32. Lee, J.K.; Zaidi, S.H.; Liu, P.; Dawood, F.; Cheah, A.Y.; Wen, W.H.; Saiki, Y.; Rabinovitch, M. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat. Med., 1998, 4(12), 1383-1391.
33. Liu, P.; Sun, M.; Sader, S. Matrix metalloproteinases in cardiovascular disease. Can. J. Cardiol., 2006, 22(Suppl B), 25B-30B.
34. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94(6), 2493.
35. Bayes-Genis, A.; Conover, C.A.; Overgaard, M.T.; Bailey, K.R.; Christiansen, M.; Holmes, D.R. Jr.; Virmani, R.; Oxvig, C.; Schwartz, R.S. Pregnacy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med., 2001, 345(14), 1022.
36. Laine, P.; Kaartinen, M.; Penttilä, A.; Panula, P.; Paavonen, T.; Kovanen, P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct related coronary artery. Circulation, 1999, 99(3), 361.
37. Lindsey, M.L.; Zamilpa, R. Temporal and Spatial Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Following Myocardial Infarction. Cardiovasc. Ther., 2012, 30(1), 31-41.
38. Lindsey, M.L. MMP induction and inhibition in myocardial infarction. Heart. Fail. Rev., 2004, 9(1), 7-19.
39. Brinckerhoff, C.E.; Ruby, P.L.; Austin, S.D.; Fini, M.E.; White, H.D. Molecular cloning of human synovial cell collagenase and selection of a single gene from genomic DNA. Journal of Clinical Investigation, 1987, 79(2), 542-546.
40. Guenzi, E.; Töpolt, K.; Lubeseder-Martellato, C.; Jörg, A.; Naschberger, E.; Benelli, R.; Albini, A.; Stürzl, M. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO Journal, 2003, 22(15), 3772-3782.
41. Inoue, T.; Kato, T.; Takayanagi, K.; Uchida, T.; Yaguchi, I.; Kamishirado, H.; Morooka, S.; Yoshimoto, N. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am. J. Cardiol., 2003, 92(12), 1461-1464.
42. Kim, M.P.; Zhou, M.; Wahl, L.M. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J. Leukoc. Biol., 2005, 78(1), 195-201.
43. Han, Y.L.; Wu, Z.F.; Zhang, X.L.; Yan, C.H.; Yang, Y.; Xi, S.Y.; Kang, J. Matrix metalloproteinase-1 gene -519A/G polymorphism and the risk of coronary heart disease in Northern Chinese Han population. Zhonghua Xin Xue Guan Bing Za Zhi, 2008, 36(3), 195-198.
44. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (New York, N.Y.), 1999, 284(5420), 1667-1670.
45. Li, A.; Varney, M.L.; Valasek, J.; Godfrey, M.; Dave, B.J.; Singh, R.K. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis, 2005, 8(1), 63-71.
46. Philip, S.; Bulbule, A.; Kundu, G.C. Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate journal, 2004, 21(8-9), 429-441.
47. Stetler-Stevenson, W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. The Journal of clinical investigation, 1999, 103(9), 1237-1241.
48. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annual review of cell and developmental biology, 2001, 17, 463-516.
49. Nandy, D.; Mukhopadhyay, D. Growth Factor Mediated Signaling in Pancreatic Pathogenesis. Cancers, 2011, 3(1), 841-871.
50. Gresele, P.; Falcinelli, E.; Loffredo, F.; Cimmino, G.; Corazzi, T.; Forte, L.; Guglielmini, G.; Momi, S.; Golino, P. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur. Heart. J., 2011, 32(3), 316-325.
51. Dhillon, O.S.; Khan, S.Q.; Narayan, H.K.; Ng, K.H.; Mohammed, N.; Quinn, P.A.; Squire, I.B.; Davies, J.E.; Ng, L.L. Matrix metalloproteinase- 2 predicts mortality in patients with acute coronary syndrome. Clin. Sci. (Lond)., 2009, 118(4), 249-57.
52. Kai, H.; Ikeda, H.; Yasukawa, H.; Kai, M.; Seki, Y.; Kuwahara, F.; Ueno, T.; Sugi, K.; Imaizumi, T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 1998, 32(2), 368-372.
53. Zeng, B.; Prasan, A.; Fung, K.C.; Solanki, V.; Bruce, D.; Freedman, S.B.; Brieger, D. Elevated circulating levels of matrix metalloproteinase- 9 and -2 in patients with symptomatic coronary artery disease. Intern. Med. J., 2005, 35(6), 331-335.
54. Hui, B.; Dang, Q.; Wang, X.F.; Jin, Z.; Xia, D.S.; Gao, L.; Cai, L.; Zhang, J. Xu, F.; Wang, P.X. Intravascular ultrasound study of coronary remodeling and determination of matrix metalloproteinase and hypersensitive C-reactive protein. Zhonghua Xin Xue Guan Bing Za Zhi, 2005, 33(5), 428-432.
55. Fitzsimmons, P.J.; Forough, R.; Lawrence, M.E.; Gantt, D.S.; Rajab, M.H.; Kim, H.; Weylie, B.; Spiekerman, A.M.; Dehmer, G.J. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis, 2007, 194(1), 196-203.
56. Kaludercic, N.; Lindsey, M.L.; Tavazzi, B.; Lazzarino, G.; Paolocci, N. Inhibiting Met-aletal/et-alloproteases with PD 166793 in Heart Failure: Impact on Cardiac Remodeling and Beyond. Cardiovasc. Ther., 2008, 26(1), 24-37.
57. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L.E.; Schoen, F.J.; Kelly, R.A.; Werb, Z.; Libby, P.; Lee, R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest., 2000, 106(1), 55-62.
58. Liu, C.P.; Yeh, J.L.; Wu, B.N.; Chai, C.Y.; Chen, I.J.; Lai, W.T. KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP- 9/TIMP-1 balance. Br. J. Pharmacol., 2011, 162(1), 126-135.
59. Lindsey, M.L.; Wedin, K.; Brown, M.D.; Keller, C.; Evans, A.J.; Smolen, J.; Burns, A.R.; Rossen, R.D.; Michael, L.; Entman, M. Matrix-Dependent Mechanism of Neutrophil-Mediated Release and Activation of Matrix Metalloproteinase 9 in Myocardial Ischemia/ Reperfusion. Circulation, 2001, 103(17), 2181.
60. Derosa, G.; Cicero, A.F.; Scalise, F.; Avanzini, M.A.; Tinelli, C.; Peros, E.; Fogari, E.; D'Angelo, A. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium, 2007, 14(4-5), 175-183.
61. Derosa, G.; D'Angelo, A.; Scalise, F.; Avanzini, M.A.; Tinelli, C.; Peros, E.; Fogari, E.; Cicero, A.F. Comparison between metalloproteinases- 2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart. Vessels., 2007, 22(6), 361-370.
62. Nagase, H.; Visse, R.; Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 2006, 69(3), 562-573.
63. Qiang, H.; Zhou, Z.X.; Ma, A.Q.; Cheng, H.; Zhou, P. Implications of serum matrix metalloproteinase-8 elevation in patients with acute coronary syndrome. Nan Fang Yi Ke Da Xue Xue Bao, 2007, 27(6), 831-833.
64. Shah, V.K.; Shalia, K.K.; Mashru, M.R.; Soneji, S.L.; Abraham, A.; Kudalkar, K.V.; Vasvani, J.B.; Sanghavi, S.T. Role of matrix metalloproteinases in coronary artery disease. Indian Heart. J., 2009, 61(1), 44-50.
65. Hornebeck, W. Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. Pathol. Biol., 2004, 51(10), 569-573.
66. Gardner, J.; Ghorpade, A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J. Neurosci. Res., 2004, 74(6), 801-806.
67. Inokubo, Y.; Hanada, H.; Ishizaka, H.; Fukushi, T.; Kamada, T.; Okumura, K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart. J., 2001, 141(2), 211-217.
68. Zhang, X.W.; Ge, J.B.; Yang, J.M.; Ge, L.; Wang, N.F.; Gao, Y.; Li, P.Z.; Pan, H.; Tong, G.X.; Zhou, L.; Ye, X.H.; Xu, J. Relationship between hs-CRP, proMMP-1, TIMP-1 and coronary plaque morphology: intravascular ultrasound study. Chin. Med. J. (Engl)., 2006, 119(20), 1689-1694.
69. Giansante, C.; Fiotti, N.; Di Chiara, A.; Altamura, N.; Wasserman, S.; Fioretti, P.; Guarnieri, G. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers. J. Cardiovasc. Med. (Hagerstown)., 2007, 8(8), 602-607.
70. Cheng, M.; Hashmi, S.; Mao, X.; Zeng, Q.T. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can. J. Cardiol., 2008, 24(5), 385-390.
71. Tan, J.; Hua, Q.; Gao, J.; Fan, Z.X. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase- 9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin. Cardiol., 2008, 31(9), 413-418.
72. Stetler-Stevenson, W.G.; Krutzsch, H.C.; Liotta, L.A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem., 1989, 264(29), 17374-17378.
73. Stetler-Stevenson, W.G.; Seo, D.W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends. Mol. Med., 2005, 11(3), 97-103.
74. Kułach, A.; Dabek, J.; Głogowska-Ligus, J.; Garczorz, W.; Gasior, Z. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes. Pharmacol. Rep., 2010, 62(6), 1108-1116.
75. Nanni, S.; Melandri, G.; Hanemaaijer, R.; Cervi, V.; Tomasi, L.; Altimari, A.; Van Lent, N.; Tricoci, P.; Bacchi, L.; Branzi, A. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Trans.l Res., 2007, 149(3), 137-144.
76. Fujiwara, T.; Saito, S.; Osanai, T.; Kameda, K.; Abe, N.; Higuma, T.; Yokoyama, J.; Hanada, H.; Fukui, K.; Fukuda, I.; Okumura, K. Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin. Eur. J. Pharmacol., 2008, 594(1-3), 146-151.
77. Gómez-Hernández, A.; Sánchez-Galán, E.; Ortego, M.; Martín- Ventura, J.L.; Blanco-Colio, L.M.; Tarín-Vicente, N.; Jiménez- Nacher, J.J.; López-Bescos, L.; Egido, J.; Tuñón, J. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase- 9 activity in the plasma of patients with non-STelevation acute coronary syndrome. Am. J. Cardiol., 2008, 102(1), 12-18.
78. D'Annunzio, V.; Donato, M.; Erni, L.; Miksztowicz, V.; Buchholz, B.; Carrión, C.L.; Schreier, L.; Wikinski, R.; Gelpi, R.J.; Berg, G.; Basso, N. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol., 2009, 53(2), 137-144.
79. Tousoulis, D.; Andreou, I.; Tentolouris, C.; Antoniades, C.; Papageorgiou, N.; Gounari, P.; Kotrogiannis, I.; Miliou, A.; Charakida, M.; Trikas, A.; Stefanadis, C. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int. J. Cardiol., 2010, 145(3), 438-443.
80. Cevik, C.; Otahbachi, M.; Nugent, K.; Warangkana, C.; Meyerrose, G. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. J. Cardiovasc. Med. (Hagerstown)., 2008, 9(12), 1274-1278.
81. Romero-Perez, D.; Fricovsky, E.; Yamasaki, K.G.; Griffin, M.; Barraza-Hidalgo, M.; Dillmann, W.; Villarreal, F. Cardiac Uptake of Minocycline and Mechanisms for In Vivo Cardioprotection. J. Am. Coll. Cardiol., 2008, 52(13), 1086-1094.
82. Lau, A.C.; Duong, T.T.; Ito, S.; Wilson, G.J.; Yeung, R.S. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin. Exp. Immunol., 2009, 157(2), 300-309.
83. Tran, E.D.; DeLano, F.A.; Schmid-Schönbein, G.W. Enhanced Matrix Metalloproteinase Activity in the Spontaneously Hypertensive Rat: VEGFR-2 Cleavage, Endothelial Apoptosis, and Capillary Rarefaction. J. Vasc. Res., 2010, 47(5), 423-431.
84. Yoshiyama, M.; Nakamura, Y.; Omura, T.; Izumi, Y.; Matsumoto, R.; Oda, S.; Takeuchi, K.; Kim, S.; Iwao, H.; Yoshikawa, J. Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart, 2005, 91(8), 1080-1085.
85. Yamamoto, D.; Takai, S.; Miyazaki, M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochemical and Biophysical Research Communications, 2007, 354(4), 981-984.
86. Jin, Y.; Han, H.C.; Lindsey, M.L. ACE Inhibitors to Block MMP-9 Activity: New Functions for Old Inhibitors. J. Mol. Cell. Cardiol., 2007, 43(6), 664-666.
87. Yamazaki, K.G.; Romero-Perez, D.; Barraza-Hidalgo, M.; Cruz, M.; Rivas, M.; Cortez-Gomez, B.; Ceballos, G.; Villarreal, F. Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart. Circ. Physiol., 2008, 295(2), H761-767.
88. Suzuki, J.; Ogawa, M.; Maejima, Y.; Isobe, K.; Tanaka, H.; Sagesaka, Y.M.; Isobe, M. Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. J. Mol. Cell. Cardiol., 2007, 42(2), 432-440.
89. Gao, P.; Guo, R.W.; Chen, J.F.; Chen, Y.; Wang, H.; Yu, Y.; Huang, L. A meprin inhibitor suppresses atherosclerotic plaque formation in ApoE-/- mice. Atherosclerosis, 2009, 207(1), 84-92.
90. Kruse, M.N.; Becker, C.; Lottaz, D. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloproteinase inhibitors. Biochem. J., 2004, 378 (Pt 2), 383-389.
91. Selvendiran, K.; Kuppusamy, M.L.; Bratasz, A.; Tong, L.; Rivera, B.K.; Rink, C.; Sen, C.K.; Kálai, T.; Hideg, K.; Kuppusamy, P. Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through upregulation of PTEN expression. J. Pharmacol. Exp. Ther., 2009, 329(3), 959-966.
92. Lindsey, M.L.; Escobar, G.P.; Dobrucki, L.W.; Goshorn, D.K.; Bouges, S.; Mingoia, J.T.; McClister, D.M. Jr.; Su, H.; Gannon, J.; MacGillivray, C.; Lee, R.T.; Sinusas, A.J.; Spinale, F.G. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart. Circ. Physiol., 2006, 290(1), H232-239.
93. Shao, H.; Tan, Y.; Eton, D.; Yang, Z.; Uberti, M.G.; Li, S.; Schulick, A.; Yu, H. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells, 2008, 26(5), 1376-1384.
94. Fingleton, B. MMPs as therapeutic targets--still a viable option? Semin. Cell. Dev. Biol., 2008, 19(1), 61-68.
95. Lim, C.S.; Shalhoub, J.; Gohel, M.S.; Shepherd, A.C.; Davies, A.H. Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target? Current Vascular Pharmacology, 2010, 8(1), 75-85.
96. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug. Discov. Today., 2007, 12(15-16), 640-646.
97. Shah, F.; Balan, P.; Weinberg, M.; Reddy, V.; Neems, R.; Feinstein, M.; Dainauskas, J.; Meyer, P.; Goldin, M.; Feinstein, S.B. Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: a new surrogate marker of atherosclerosis? Vasc. Med., 2007, 12(4), 291-297.